Literature DB >> 16455536

Vestibular schwannoma management: What is the 'best' option?

S A Rutherford1, A T King.   

Abstract

There is an abundance of medical literature describing the management options for vestibular schwannomas. However, the lack of high quality clinical trials means that, for any individual patient, the decision is often based on the clinician's personal biases. The management options that are available are conservative treatment, surgery, single-dose stereotactic radiosurgery and fractionated radiotherapy. In this review, we set out what the aims of managing a vestibular schwannoma should be and compare how these different treatment modalities perform. The particular objectives of tumour control, cranial nerve preservation, prevention of malignancy, quality of life and cost-effectiveness are discussed. It remains difficult to differentiate between these methods when more than one is suitable; the literature confirms that they are all safe and effective, but the decision must be the patient's, based on their individual priorities. This review should equip the clinician to provide an informed overview of the options.

Entities:  

Mesh:

Year:  2005        PMID: 16455536     DOI: 10.1080/02688690500305399

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  14 in total

Review 1.  Surgery of the ear and the lateral skull base: pitfalls and complications.

Authors:  Bernhard Schick; Julia Dlugaiczyk
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2013-12-13

2.  Comparison between VII-to-VII and XII-to-VII coaptation techniques for early facial nerve reanimation after surgical intra-cranial injuries: a systematic review and pooled analysis of the functional outcomes.

Authors:  Luca Ricciardi; Vito Stifano; Resi Pucci; Vittorio Stumpo; Nicola Montano; Marco Della Monaca; Liverana Lauretti; Alessandro Olivi; Valentino Valentini; Carmelo Lucio Sturiale
Journal:  Neurosurg Rev       Date:  2020-01-07       Impact factor: 3.042

3.  A case of high-grade undifferentiated sarcoma after surgical resection and stereotactic radiosurgery of a vestibular schwannoma.

Authors:  Tong Yang; Jason Rockhill; Donald E Born; Laligam N Sekhar
Journal:  Skull Base       Date:  2010-05

4.  Treatment decision-making for sporadic small vestibular schwannoma in a pediatric patient: A case report and literature review.

Authors:  Jun Wang; Yajing Xu; Ting Lei; Liang Zeng
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

Review 5.  [Value of different strategies in the treatment of vestibular schwannoma: therapeutic aspects and literature analysis].

Authors:  W Maier; T D Grauvogel; R Laszig; G J Ridder
Journal:  HNO       Date:  2011-05       Impact factor: 1.284

6.  Revision Surgery for Vestibular Schwannomas.

Authors:  Kevin A Peng; Brian S Chen; Mark B Lorenz; Gregory P Lekovic; Marc S Schwartz; William H Slattery; Eric P Wilkinson
Journal:  J Neurol Surg B Skull Base       Date:  2018-04-09

7.  Does where you live influence how your vestibular schwannoma is managed? Examining geographical differences in vestibular schwannoma treatment across the United States.

Authors:  Matthew L Carlson; Amy E Glasgow; Brandon R Grossardt; Elizabeth B Habermann; Michael J Link
Journal:  J Neurooncol       Date:  2016-06-22       Impact factor: 4.130

8.  Multifactor Influences of Shared Decision-Making in Acoustic Neuroma Treatment.

Authors:  Jason C Nellis; Jeff D Sharon; Seth E Pross; Lisa E Ishii; Masaru Ishii; Jacob K Dey; Howard W Francis
Journal:  Otol Neurotol       Date:  2017-03       Impact factor: 2.311

9.  Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation.

Authors:  Wei Ying Yue; J Jason Clark; Michael Telisak; Marlan R Hansen
Journal:  Neurosurgery       Date:  2013-09       Impact factor: 4.654

10.  EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Authors:  Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.